Granules India and Ajinomoto OmniChem create jv in India
Granules OmniChem will operate an API and intermediates facility in Vishakhapatnam, Andhra Pradesh
The new company, Granules-OmniChem, will build a US$20m plant in the Pharmacity SEZ zone in Vishakhapatnam, Andhra Pradesh, initially to manufacture high-value, low-volume APIs and intermediates.
Construction of the facility will start in November and should be completed towards the end of 2012.
The jv aims to capitalise on demand from pharmaceutical firms which are outsourcing their manufacturing needs at a time when the industry is focused on the US$234bn generics market. More than 80% of API production is for the generics market.
Granules-Omnichem will focus on producing APIs and intermediates for existing customers of both partners and in the future manufacture new chemical entities.
‘Our shareholders will benefit since this will enable Granules to diversify its business by offering high value APIs and intermediates which will increase our profitability,’ said Krishna Prasad, managing director of Granules.
Gwin Bompas, managing director of Ajinomoto OmniChem, which employs around 700 people at three sites in Belgium, said the jv would enable the firm to ‘offer access to quality medicine at an affordable price for the market’.
Granules India manufactures finished dosage forms, pharmaceutical intermediates and APIs, which are distributed in more than 50 countries.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
From bespoke to scalable: closing the manufacturing gap in advanced therapeutics
Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics
Manufacturing
Piramal Pharma Solutions announces partnership with Botanix to support drug substance development
Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra. Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis. Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra
Manufacturing
ProtaGene and Merck partner to deliver end-to-end biologics testing
The duo will combine ProtaGene's early-stage biologics expertise with Merck's BioReliance GMP testing infrastructure, offering biopharmaceutical customers an integrated testing solution across the full drug development lifecycle
Manufacturing
Roche and MPP strike licence deal to unlock generic baloxavir access across 129 LMICs
A new voluntary licence agreement between Roche and the Medicines Patent Pool will enable generic manufacturers to produce baloxavir marboxil across low- and middle-income countries (LMICs) for the first time